(Q30357127)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24360892%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24360892%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

0 references

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24360892%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Matthew D Snape

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24360892%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

2

Matthew D Snape

1 reference

20 June 2017

Charlotte I S Barker

1

1 reference

20 June 2017

publication date

19 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24360892%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

3 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24360892%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24360892%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24360892%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

227-238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24360892%20AND%20SRC:MED&resulttype=core&format=json

Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Prospects for controlling future pandemics of influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Recognition and management of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Safety of pandemic H1N1 vaccines in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Regulators face tough flu-jab choices

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Monitoring and assessing vaccine safety: a European perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Under-reporting of adverse drug reactions : a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Guillain-Barré syndrome after exposure to influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Post-H1N1 narcolepsy-cataplexy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Pandemrix°, (H1N1)v influenza and reported cases of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea: an ecological study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

RETRACTION: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

MMR vaccine--worries are not justified

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

MMR vaccine and autism.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Duty to warn?-the ethics of disclosing information about possible risks associated with H1N1 vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

Adaptive licensing: taking the next step in the evolution of drug approval

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970238-X

7 January 2021

10.1016/S1473-3099(13)70238-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24360892%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference